Key result
A dedicated cardio-oncology unit in Heidelberg successfully assessed over 2,000 cancer patients, demonstrating the feasibility of a standardized, interdisciplinary approach to manage cardiovascular comorbidities and toxicities.
Why the study?
Thrombi and spontaneous echo contrast (SEC) in the left atrial appendage are associated with thromboembolic events, but data on long-term outcomes with direct acting anticoagulants are limited.
Does the choice of DOAC therapy (apixaban vs dabigatran) impact the rate of major adverse cardiovascular and cerebrovascular events in patients with LAA thrombus or SEC?
Does the choice of DOAC therapy (apixaban vs dabigatran) impact the rate of major adverse cardiovascular and cerebrovascular events in patients with LAA thrombus or SEC?
In patients with LAA thrombus or SEC, the choice of DOAC therapy may significantly impact long-term outcomes, with apixaban associated with fewer adverse events compared to dabigatran.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lehmann et al. (2021) conducted a letter in Cancer (Cardio-oncology) (n=2,000). Cardio-oncology unit (COUNT) care model was evaluated. A dedicated cardio-oncology unit in Heidelberg successfully assessed over 2,000 cancer patients, demonstrating the feasibility of a standardized, interdisciplinary approach to manage cardiovascular comorbidities and toxicities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: